Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020
Influence of basal FEV1 on the response to bronchodilator agents in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001
Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001
Maintenance plus as-needed budesonide/formoterol vs salmeterol/fluticasone in a real-life setting Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
How often FEV1 underestimates bronchodilator response? Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008
Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003
Normal lung function and absence of bronchodilator response in children with stable, controlled asthma using inhaled corticosteroids Source: Annual Congress 2006 - New features of paediatric asthma Year: 2006
FEV1 response to albuterol is not affected by inhaled human insulin (Exubera®) use in subjects with mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 840s Year: 2006
Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 512s Year: 2004
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013
IsovolumeFEF25-75% 6 and FEV1 for identifying bronchodilator response Source: Eur Respir J 2006; 28: Suppl. 50, 156s Year: 2006
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo Source: Eur Respir J 2006; 28: Suppl. 50, 764s Year: 2006
Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 89s Year: 2004